The numbers behind Tysabri, a key monoclonal antibody for multiple sclerosis and Crohn’s disease, reveal a market that is both expanding and evolving—with autoimmune disorder rates and precision medicine trends pushing growth. A new report from The Business Research Company breaks down the data.
The Business Research Company’s Tysabri (natalizumab) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
Recent analysis shows that the Tysabri (natalizumab) market has experienced notable expansion in recent years, fueled by factors tied to disease prevalence and ongoing medical progress. As the healthcare environment continues to shift, this market is anticipated to grow steadily, bolstered by advances in diagnosis, treatment delivery systems, and patient management approaches. What follows is a comprehensive look at market size, driving forces, emerging trends, and regional dynamics.
Also worth a look: Oriient study finds one-third of grocery out-of-stock complaints are actually items sitting on shelves and Advanced aerospace materials market poised to hit $32.28B by 2030 as plane orders soar 537%.
Steady Expansion of the Tysabri (natalizumab) Market Size
The market for Tysabri has grown robustly, climbing from $2.66 million in 2025 to an expected $2.87 million in 2026, reflecting a compound annual growth rate (CAGR) of 8.1%. This upward trajectory is largely attributed to the increasing prevalence of multiple sclerosis (MS), regulatory approvals for natalizumab, broader acceptance among neurologists, unmet needs in managing aggressive MS, and the expansion of infusion centers. Looking forward, projections indicate the market could reach $3.87 million by 2030, with a slightly moderated CAGR of 7.8%. Forecasted growth is supported by improved MS diagnosis rates, enhanced infusion infrastructure, stronger risk management programs, growing specialty neurology services, and sustained focus on long-term clinical outcomes. Key trends shaping the period include rising use of monoclonal antibodies for MS, a shift toward highly effective disease-modifying therapies, growth in outpatient infusion care, better safety monitoring, and increased attention to managing progressive forms of MS.
Download a free sample of the Tysabri (natalizumab) market report:
https://thebusinessresearchcompany.com/sample_request?id=40164192&type=smp&name=Tysabri%20%28natalizumab%29%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
Understanding Tysabri’s Role in Treating Multiple Sclerosis and Crohn’s Disease
Tysabri, a monoclonal antibody, is primarily prescribed for relapsing forms of multiple sclerosis and Crohn’s disease, working to reduce inflammation and nerve damage. The drug achieves this by lowering relapse frequency and slowing physical disability progression in adults with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS). Its mechanism of action makes it a critical treatment option for patients facing these difficult autoimmune conditions.
The Impact of Rising Autoimmune Disorder Cases on Tysabri Market Growth
A key driver behind the expansion of the Tysabri market is the growing global incidence of autoimmune disorders. These diseases occur when the immune system mistakenly attacks the body’s own tissues, resulting in chronic conditions such as multiple sclerosis and rheumatoid arthritis. The rise is linked to genetic predispositions, environmental triggers, and improved diagnosis and awareness. Because Tysabri specifically targets immune cells responsible for inflammation, it offers an effective therapeutic option. For example, Arthritis Australia reported that by 2025, nearly 562,378 Australians are expected to have rheumatoid arthritis, representing 14% of the total arthritis population. Data like this underscores the increasing market demand for treatments such as Tysabri.
View the full Tysabri (natalizumab) market report:
https://thebusinessresearchcompany.com/report/tysabri-natalizumab-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
Personalized Medicine Boosts Demand for Tysabri (natalizumab)
The growing focus on personalized medicine is also accelerating Tysabri market growth. This approach tailors treatments to individual genetic profiles, environmental factors, and lifestyle choices to enhance effectiveness and minimize side effects. Advances in genomic technologies and precision diagnostics have sped up this trend. Tysabri exemplifies personalized therapy by offering targeted treatment for relapsing MS patients with specific disease activity and risk factors, thereby optimizing benefits while reducing adverse reactions. The Personalized Medicine Coalition noted that in 2023, the FDA approved 16 new personalized therapies for rare diseases—seven for cancer and three for other conditions—compared to just six approvals in 2022. This rising preference for customized treatment strategies supports continued market expansion for Tysabri.
Regional Market Leadership and Growth Forecasts for Tysabri
Geographically, North America held the largest share of the Tysabri market in 2025. However, the Asia-Pacific region is projected to experience the fastest growth over the forecast period. The market analysis covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a global view.
New additions to our 2026 reports:
- Market attractiveness scoring and analysis
- Total addressable market (TAM) analysis
- Company scoring matrix graphics and tables
- Excel-based forecasting dashboards
- Market hotspots infographics
- Key technologies and future trend analysis
- Updated graphics and tables
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: As autoimmune diseases like multiple sclerosis and rheumatoid arthritis become more common globally, the market for targeted therapies such as Tysabri is set to grow—especially with the shift toward personalized medicine. Understanding these trends helps clinicians, investors, and policymakers anticipate where treatment demand and innovation will focus next.
